NCT04724798

Population Pharmacokinetics of Tigecycline in Patients Treated With ECMO

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 10 (estimated)
• Sponsor: Nanfang Hospital, Southern Medical University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Tigecycline is a commonly used antibiotic in critically ill patients. The pharmacokinetics (PK) of tigecycline in intensive care unit (ICU) patients can be affected by severe pathophysiological changes so that standard dosing might not be adequate. At present, a number of studies have reported that ECMO will affect the PK of anti-infective drugs and lead to treatment failure. The purpose of this study was to describe the population PK of tigecycline in patients treated with ECMO and to evaluate the relationship between individual PK parameters and patient covariates.

Conditions

• Extracorporeal Membrane Oxygenation
• Pharmacokinetics
• Tigecycline

Timeline

• Start date: 2020-01-20
• Primary completion: 2022-12-30
• Completion: 2022-12-30
• First posted: 2021-01-26
• Last updated: 2021-01-26

Locations

1 site across 1 country: China